Leo Pharma applauds new WHO resolution on psoriasis stigma

Leo Pharma has responded positively to news that the World Health Organization (WHO) has signed a historic resolution in support of psoriasis patients worldwide.

The global health body has vowed to fight the stigma suffered by people with the chronic skin disease, which affects more than 125 million individuals. It marks the first time a standalone resolution on psoriasis has been on the agenda at the World Health Assembly.

Acknowledging that psoriasis is highly stigmatised and can have serious physical as well as psychosocial implications for patients, the document contains a series of action points that aim to improve the quality of life for sufferers.

These include raising awareness of the condition and making information more accessible, while emphasising the importance of holistic care. The WHO has also committed to delivering a global report on psoriasis in 2015.

Kim Kjoeller, senior vice-president for global development at Leo Pharma, said: "Today marks a milestone for psoriasis patients. This groundbreaking development is a clear sign that psoriasis has finally moved higher up the international health agenda."

Psoriasis is one of the key areas of strategic focus for Leo Pharma, which distributes a wide range of dermatology products, including Dovobet, Fucidin, Picato and sodium fusidate.